Kornitzer Capital Management Inc. KS Boosts Stock Holdings in Repligen Corporation $RGEN

Kornitzer Capital Management Inc. KS boosted its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 7.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 83,780 shares of the biotechnology company’s stock after acquiring an additional 5,500 shares during the period. Kornitzer Capital Management Inc. KS owned 0.15% of Repligen worth $13,728,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Horizon Investments LLC purchased a new position in Repligen during the fourth quarter valued at $84,000. Fifth Third Bancorp grew its stake in Repligen by 19.7% during the fourth quarter. Fifth Third Bancorp now owns 3,772 shares of the biotechnology company’s stock valued at $618,000 after acquiring an additional 622 shares in the last quarter. Conestoga Capital Advisors LLC grew its stake in Repligen by 10.6% during the fourth quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock valued at $173,360,000 after acquiring an additional 101,062 shares in the last quarter. Oppenheimer & Co. Inc. grew its stake in Repligen by 8.2% during the fourth quarter. Oppenheimer & Co. Inc. now owns 1,623 shares of the biotechnology company’s stock valued at $266,000 after acquiring an additional 123 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its stake in Repligen by 6.4% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 17,925 shares of the biotechnology company’s stock valued at $2,937,000 after acquiring an additional 1,077 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

RGEN stock opened at $117.20 on Friday. Repligen Corporation has a 12 month low of $109.50 and a 12 month high of $175.77. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average price of $121.56 and a 200 day moving average price of $144.73. The stock has a market cap of $6.61 billion, a PE ratio of 137.88, a P/E/G ratio of 2.31 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The firm had revenue of $197.91 million during the quarter, compared to analysts’ expectations of $192.23 million. During the same period in the previous year, the company earned $0.44 EPS. The firm’s revenue for the quarter was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities research analysts anticipate that Repligen Corporation will post 1.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. KeyCorp reissued an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Wells Fargo & Company dropped their price objective on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. UBS Group dropped their price objective on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. Roth Mkm assumed coverage on shares of Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 price objective for the company. Finally, Weiss Ratings cut shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $170.25.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.